Objectives: There have been three eras in the development of EVAR: physician-made and early industry devices, intermediary commercial endografts, and modern stentgrafts. This study analyzed the differences in outcomes between these three groups.
Methods: From 1992-2012, 1290 patients underwent elective EVAR. Fifteen different devices were used during this time. The three eras were defined as: Era1: 1992-96; Era2: 1997 Era2: -2006 Era3: 2007 Era3: -2012 . Grafts used in each era were: Era1: physician-made and EVT; Era2: Talent, Aneurx, Excluder, Quantum LP, Zenith, Vangaurd, PG AAA, Ancure, Endologix, and Teramed; Era3: Talent, Aneurx, Endurant, Excluder, Zenith, and Aptus.
Results: Mean age was 75.2 years and 85% were men. First generation patients were higher surgical risk (Mean Glasgow Aneurysm Scores: Era1 84.81 vs Era3: 79.95, P ¼ .048). Adjunctive procedures increased from Era1 to Era3 (P ¼ .014). Procedure times (P < .001), Blood loss (P ¼ .01), and Length of stay (P < .001) have declined overtime. Major peri-operative complications (Era1: 23%, Era2: 9.2%, and Era3: 4.5%; P < .001) and AAA-related peri-operative mortality (Era1: 17.6%, Era2: 2.3%, and Era3: 0.0%; P < .001) have decreased. Type 1 and 3 endoleaks (P ¼ .011) and the need for reintervention (P < .001) have diminished. Median survival for all causes of death and freedom from aneurysm-related mortality significantly improved (Fig) .
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